BRIEF-Tnf Pharmaceuticals Announces Trial To Explore Effects Of Lead Candidate In Sarcopenia/Frailty Induced By Glp-1 Weight Loss Drugs

Reuters
19 Dec 2024
BRIEF-Tnf Pharmaceuticals Announces Trial To Explore Effects Of Lead Candidate In Sarcopenia/Frailty Induced By Glp-1 Weight Loss Drugs

Dec 19 (Reuters) - TNF Pharmaceuticals Inc TNFA.O:

  • TNF PHARMACEUTICALS ANNOUNCES TRIAL TO EXPLORE EFFECTS OF LEAD CANDIDATE IN SARCOPENIA/FRAILTY INDUCED BY GLP-1 WEIGHT LOSS DRUGS

  • FULLY FUNDED STUDY TO EVALUATE WEGOVY AND OZEMPIC PATIENTS AT RISK FOR INCREASED INFLAMMATION ASSOCIATED WITH SARCOPENIC MUSCLE DETERIORATION

  • ENTERS COLLABORATIVE AGREEMENT WITH RENOVA HEALTH

Source text: ID:nBw9jKjzfa

Further company coverage: TNFA.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10